Molnupiravir 1 is a nucleoside analogue currently in the advanced stages of clinical trials for the treatment of Covid-19 . Positive clinical data prompted early termination of recent phase 3 trials in order to seek emergency use authorization to treat adult patients with mild-to-moderate Covid-19 who are at risk of progressing to severity or hospitalization. The structural simplicity of Molnupiravir compared to alternative therapies (e.g. Remdesivir), combined with its oral availability and broadspectrum antiviral activities, make it an attractive candidate for the global treatment of viral infections. In view of the urgent need to develop therapies for treating the Covid-19 pandemic there has been considerable interest in developing synthetic routes to this API. The original synthesis required 10 steps and proceeded with <10% overall yield . More streamlined approaches have subsequently been reported , however these routes rely on chemical methods to install the Nhydroxy unit, which require elevated temperatures, prolonged reaction times, and/or additional steps for activation and protection/deprotection chemistry. These factors compromise reaction yields and process productivity, ultimately leading to increased costs.